CoChat

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment

Open access
Hanefeld, Markolf, Arteaga, Juan M., Leiter, Lawrence A., Marchesini, Giulio, Nikonova, Elena, Shestakova, Marina, Stager, William, Gómez‐Huelgas, Ricardo · 2017 · Diabetes, Obesity and Metabolism
Cited by 22

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Aims: This post hoc assessment evaluated the efficacy and safety of once‐daily, prandial glucagon‐like peptide‐1 receptor agonist lixisenatide in patients with type 2 diabetes ( T2D ) and normal renal function (estimated glomerular filtration rate ≥90 mL /min), or mild (60‐89 mL /min) or moderate (30‐59 mL /min) renal impairment. Methods: Patients from 9 lixisenatide trials in the GetGoal clinical trial programme were categorized by baseline creatinine clearance: normal renal function (lixisenatide n = 2094, placebo n = 1150); renal impairment (mild: lixisenatide n = 637, placebo n = 414; moderate: lixisenatide n = 122, placebo n = 68). Meta‐analyses of placebo‐adjusted mean differences between baseline renal categories were performed for efficacy and safety outcomes. Results: HbA1c , 2‐hour postprandial plasma glucose and fasting plasma glucose were comparably reduced in lixisenatide‐treated patients with normal renal function, and mild and moderate renal impairment. The most common adverse events ( AEs ) in all renal function categories were gastrointestinal ( GI ), predominantly nausea and vomiting. A 14% higher incidence of GI AEs and a 10% higher incidence of nausea and vomiting were seen with mild impairment vs normal function ( P = .003 for both), but no significant differences were observed between the mild and moderate impairment categories ( P = .99 and P = .57, respectively), or between the moderate impairment and normal categories ( P = .16 and P = .65, respectively). Additionally, the incidence of hypoglycaemia was similar in all categories. Conclusions: This study demonstrates that baseline renal status does not affect efficacy outcomes in lixisenatide‐ vs placebo‐treated patients, and that no lixisenatide dose adjustment is required for patients with T2D with mild or moderate renal impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12986

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 22

Metadata

Authors
Hanefeld, M., Arteaga, J. M., Leiter, L. A., Marchesini, G., Nikonova, E., Shestakova, M., Stager, W., & Gómez‐Huelgas, R.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-06-07
Volume
19
Issue
11
Pages
1594-1601
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2607581455
Cited by
22
References
13
FWCI
2.23
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. https://app.cochat.ai/papers/10.1111/dom.12986
The paper
Hanefeld, M., Arteaga, J. M., Leiter, L. A., Marchesini, G., Nikonova, E., Shestakova, M., Stager, W., & Gómez‐Huelgas, R. (2017). Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12986

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.